The Prognostic Impact of WT۱ Expression Levels, Mutations, and SNP rs۱۶۷۵۴ in AML Patients: A Retrospective Cohort Study

 Background and Objective: The clinical outcomes and treatment options for acute myeloid leukemia (AML) patients are highly dependent upon molecular markers. In this study, Wilms tumor (WT۱) (exons ۷ and ۹) mutations, SNP rs۱۶۷۵۴, and WT۱ expression levels in ۱۳۰ random AML patients were screened; FMs-like tyrosine kinase-۳ internal tandem duplication (FLT۳-ITD), nucleophosmin (NPM۱), and CCAAT/enhancer-binding protein alpha (CEBPA) mutations were also evaluated.  Material and Methods: Overall, ۱۳۰ AML patients were recruited for our study. WT۱ mutations were determined by Sanger sequencing, and expression levels were determined by real-time PCR. The Kaplan-Meier method was used to calculate overall survival (OS) and disease-free survival (DFS).  Results: The frequency of WT۱ mutations in the study population was ۵.۴%, and it did not affect overall survival (OS) (p=۰.۹۸), disease-free survival (DFS) (p=۰.۹۷), or complete remission (CR) rates in AML patients. The major allele of SNP rs۱۶۷۵۴ in the current study was A. No significant differences were found for OS (p=۰.۵۲), DFS (p=۰.۴۲), or complete remission rates among all SNP rs۱۶۷۵۴ genotypes. The overexpression of WT۱ was observed in ۸۳% of patients at diagnosis. No significant difference was found for OS (p=۰.۸۴), DFS (p=۰.۸۲), or complete remission rates between AML patients with high and low WT۱ expression levels.  Conclusion: The results of the current study do not support WT۱ mutation, SNP rs۱۶۷۵۴, or WT۱ overexpression at diagnosis, as they were found to be poor prognostic markers in AML patients.

کلیدواژه ها:

AML ، WT۱ mutations ، WT۱ expression ، SNP rs۱۶۷۵۴ ، Outcomes